Literature DB >> 34140288

Collateral status reperfusion and outcomes after endovascular therapy: insight from the Endovascular Treatment in Ischemic Stroke (ETIS) Registry.

Mohammad Anadani1,2, Stephanos Finitsis3, Frédéric Clarençon4,5, Sébastien Richard6, Gaultier Marnat7, Romain Bourcier8, Igor Sibon9, Cyril Dargazanli10, Caroline Arquizan11, Raphael Blanc12, Bertrand Lapergue13, Arturo Consoli14,15, Francois Eugene16, Stephane Vannier17, Laurent Spelle18, Christian Denier19, Marion Boulanger20, Maxime Gauberti21, David S Liebeskind22, Adam de Havenon23, Suzana Saleme24, Francisco Macian25, Charlotte Rosso26, Olivier Naggara21, Guillaume Turc21, Ozlem Ozkul-Wermester27, Chrisanthi Papagiannaki27, Alain Viguier28, Christophe Cognard29, Anthony Le Bras30,31, Sarah Evain32, Valerie Wolff33, Raoul Pop34, Serge Timsit35, Jean-Christophe Gentric36, Frédéric Bourdain37, Louis Veunac38, Benjamin Maier39, Benjamin Gory40.   

Abstract

BACKGROUND: Studies have suggested that collateral status modifies the effect of successful reperfusion on functional outcome after endovascular therapy (EVT). We aimed to assess the association between collateral status and EVT outcomes and to investigate whether collateral status modified the effect of successful reperfusion on EVT outcomes.
METHODS: We used data from the ongoing, prospective, multicenter Endovascular Treatment in Ischemic Stroke (ETIS) Registry. Collaterals were graded according to the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) guidelines. Patients were divided into two groups based on angiographic collateral status: poor (grade 0-2) versus good (grade 3-4) collaterals.
RESULTS: Among 2020 patients included in the study, 959 (47%) had good collaterals. Good collaterals were associated with favorable outcome (90-day modified Rankin Scale (mRS) 0-2) (OR 1.5, 95% CI 1.19 to 1.88). Probability of good outcome decreased with increased time from onset to reperfusion in both good and poor collateral groups. Successful reperfusion was associated with higher odds of favorable outcome in good collaterals (OR 6.01, 95% CI 3.27 to 11.04) and poor collaterals (OR 5.65, 95% CI 3.32 to 9.63) with no significant interaction. Similarly, successful reperfusion was associated with higher odds of excellent outcome (90-day mRS 0-1) and lower odds of mortality in both groups with no significant interaction. The benefit of successful reperfusion decreased with time from onset in both groups, but the curve was steeper in the poor collateral group.
CONCLUSIONS: Collateral status predicted functional outcome after EVT. However, collateral status on the pretreatment angiogram did not decrease the clinical benefit of successful reperfusion. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  blood flow; stroke; thrombectomy

Mesh:

Year:  2021        PMID: 34140288     DOI: 10.1136/neurintsurg-2021-017553

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  1 in total

1.  Association of the Careggi Collateral Score with 3-month modified Rankin Scale score after thrombectomy for stroke with occlusion of the middle cerebral artery.

Authors:  Danilo Toni; Salvatore Mangiafico; Manuel Cappellari; Valentina Saia; Giovanni Pracucci; Fainardi Enrico; Arturo Consoli; Sergio Nappini; Lucio Castellan; Sandra Bracco; Mauro Bergui; Mirco Cosottini; Alessandra Briatico Vangosa; Sergio Vinci; Maria Ruggiero; Edoardo Puglielli; Luigi Chiumarulo; Giacomo Cester; Chiara Comelli; Umberto Silvagni; Daniele Morosetti; Valentina Caldiera; Nicola Cavasin; Valeria Ledda; Giuseppina Sanfilippo; Andrea Saletti; Pietro Filauri; Ivan Gallesio; Nunzio Paolo Nuzzi; Pitero Amistá; Cecilia Zivelonghi; Mauro Plebani; Marco Pavia; Daniele Romano; Francesco Biraschi; Roberto Menozzi; Roberto Gasparotti; Andrea Giorgianni; Andrea Zini; Domenico Inzitari
Journal:  J Neurol       Date:  2021-11-19       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.